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Pediatric dilated cardiomyopathy (DCM) is the most common indication for heart transplantation
in children. Despite similar genetic etiologies, medications routinely used in adult heart failure
patients do not improve outcomes in the pediatric population. The mechanistic basis for these
observations is unknown. We hypothesized that pediatric and adult DCM comprise distinct
pathological entities, in that children do not undergo adverse remodeling, the target of adult heart
failure therapies. To test this hypothesis, we examined LV specimens obtained from pediatric
and adult donor controls and DCM patients. Consistent with the established pathophysiology of
adult heart failure, adults with DCM displayed marked cardiomyocyte hypertrophy and myocardial
fibrosis compared with donor controls. In contrast, pediatric DCM specimens demonstrated
minimal cardiomyocyte hypertrophy and myocardial fibrosis compared with both age-matched
controls and adults with DCM. Strikingly, RNA sequencing uncovered divergent gene expression
profiles in pediatric and adult patients, including enrichment of transcripts associated with adverse
remodeling and innate immune activation in adult DCM specimens. Collectively, these findings
reveal that pediatric and adult DCM represent distinct pathological entities, provide a mechanistic
basis to explain why children fail to respond to adult heart failure therapies, and suggest the need to
develop new approaches for pediatric DCM.
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Dilated cardiomyopathy (DCM) is an important cause of childhood mortality and is the most common
indication for heart transplantation in the pediatric population (1–3). Despite efforts to improve patient
care, pediatric DCM remains a challenging disease with an estimated 50% 5-year transplant-free survival
(1). Within both the pediatric and adult cohorts, DCM is often associated with mutations in sarcomeric
and cytoskeletal genes (4). While the genetic basis for pediatric DCM is increasingly recognized (4), few
therapies have been developed for children suffering from this devastating disease.
Landmark clinical trials have led to the establishment of medical therapies for adults with dilated and
ischemic cardiomyopathy (5). Collectively, these therapies target a process termed adverse remodeling, a common pathway by which the adult heart responds to injury. Pathologically, adverse remodeling is defined by
cardiomyocyte hypertrophy, myocardial fibrosis, inflammation, and capillary loss (6). While it is reasonable
to postulate that adult heart failure therapies may be efficacious in children, clinical trials have not supported
this idea. Despite marked reductions in mortality associated with β-blocker therapy in adult studies, the Pediatric Carvedilol Trial failed to demonstrate improvements in clinical outcomes in children with symptomatic
heart failure (7, 8). In fact, since the implementation of digoxin and diuretic therapies decades ago, there has
been little improvement in outcomes for children with DCM (9). These observations question the effectiveness of antiremodeling therapies in children with heart failure and support the idea that, despite a common
genetic etiology (4), pediatric and adult DCM may represent distinct pathologic entities.
One potential explanation for why antiremodeling therapeutics are not effective in the pediatric population is that adverse remodeling does not govern disease progression in children. Consistent with this
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Table 1. Pediatric and adult DCM demographic data
n=
Age in yrs
Male
Diagnosis
Idiopathic
Familial
Tissue source
LVAD core
Heart explant
Age at diagnosis (yrs)
Disease duration (yrs)
Hypertension
Diabetes
Chronic kidney disease
Medications
β-Blockers
ACEi/ARB
MRAs
Diuretics
Digoxin
Hydralazine
Nitrates
Echocardiography
EF (%) [Z score]
FS (%) [Z score]
LVDD (mm) [Z score]
LVSD (mm) [Z score]

Pediatric DCM

Adult DCM

P value

31
6.5
21/31 (67.7)

34
51.0
28/34 (82.4)

<0.01
0.17

29/31 (93.5)
2/31 (6.5)

30/34 (88.2)
4/34 (11.8)

0.47
0.46

6/31 (19.4)
25/31 (80.6)
7.3
2.4
1/31 (3.2)
0/31 (0)
0/31 (0)

29/34 (85.3)
5/34 (14.7)
46.0
5.7
15/34 (44.1)
13/34 (38.2)
6/34 (17.6)

<0.01
<0.01
<0.01
0.02
<0.01
<0.01
<0.01

4/8 (50.0)
4/8 (50.0)
2/8 (25.0)
3/8 (37.5)
3/8 (37.5)
0/8 (0)
0/8 (0)

31/34 (91.1)
29/34 (85.3)
21/34 (61.2)
33/34 (97.1)
13/34 (38.2)
7/34 (20.6)
8/34 (23.5)

<0.01
0.03
0.07
<0.01
0.97
0.16
0.13

22.5 [–7.6]
11.5 [–14.2]
5.4 [9.0]
4.8 [13.7]

17.2
8.9
7.0
6.4

0.01
0.12
N/A
N/A

Percentages displayed in parenthesis. Z scores displayed in brackets for pediatric
echocardiographic data. EF, ejection fraction; FS, fractional shortening; LVDD, left
ventricular diastolic dimension (m-mode); LVSD, left ventricular systolic dimension
(m-mode); CKD, defined as stage 3 or greater chronic kidney disease; ACEi,
angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker;
MRA, mineralocorticoid receptor antagonist. Pediatric echocardiography data
represents a limited data set derived from 10 specimens. All other data is derived
from the complete sample set.

hypothesis, some hallmarks of adverse remodeling including
β-adrenergic receptor downregulation, and upregulation of
fetal gene expression appears to occur to a lesser extent in
pediatric compared with adult heart failure specimens (10).
Intriguingly, no studies have rigorously determined whether
adverse remodeling occurs in children or deciphered at what
age adverse remodeling occurs in adults. Moreover, there is a
paucity of information delineating the molecular differences
that define pediatric and adult heart failure.
To test the hypothesis that adverse remodeling does not
drive disease progression in pediatric DCM, we obtained cardiac tissue specimens from the left ventricle (LV) of pediatric
and adult patients with familial and idiopathic DCM. Using a
combination of quantitative histology, immunostaining, electron microscopy, and RNA sequencing, we show that pediatric
DCM patients do not display pathologic evidence of adverse
remodeling compared with age-matched donor control specimens. In contrast, adult patients uniformly displayed pathological evidence of adverse remodeling. Consistent with pathological evidence of adverse remodeling in adult DCM specimens,
RNA sequencing revealed that genes associated with sarcomere
remodeling, inflammation, and fatty acid metabolism were
enriched in adult compared with pediatric DCM specimens.
Collectively, these findings indicate that adverse remodeling
does not occur in children with DCM and suggest that pediatric
and adult DCM may represent distinct pathological entities.

Results

Study design. To test the hypothesis that adverse remodeling
does not occur in children with DCM, we obtained LV myocardial specimens from the apex and lateral wall of nonfailing
pediatric donor controls (n = 11), pediatric DCM patients (n =
31), adult nonfailing donor controls (n = 14), and adult DCM
patients (n = 34) (Table 1 and Supplemental Figure 1; supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.94382DS1). To our knowledge, this
represents the largest collection of pediatric and adult DCM
tissue specimens studied to date. Control tissue was obtained from unused donors with normal cardiac function by echocardiography (Table 2). DCM specimens were obtained from children and adults with advancedstage idiopathic or familial DCM at the time of cardiac transplantation or implantation of a LV assist device.
Diseased tissue specimens were further subclassified into age groups of 0–1 years (yrs) (n = 9), 1–10 yrs (n =
12), 11–18 yrs (n = 10), 19–50 yrs (n = 15), and 51–75 yrs (n = 19). To determine whether adverse remodeling
occurs in pediatric DCM, we measured cardiomyocyte and sarcomere size, myocardial fibrosis, and capillary
density in pediatric and adult donor control and DCM specimens. In addition, we performed RNA sequencing on pediatric and adult DCM specimens to examine gene expression signatures of adverse remodeling and
define pathways that differentiate pediatric from adult DCM.
Demographics. Clinical data obtained from pediatric and adult DCM patients demonstrated similar distributions of male and female subjects and comparable numbers of subjects with idiopathic and familial DCM (Table
1). Significant differences included the number of left ventricular assist device (LVAD) core and heart explant
specimens. The pediatric DCM group had a greater number of heart explant specimens, while the adult DCM
group had a greater number of LVAD core specimens. In addition, disease duration was longer in adult DCM
subjects, and the frequency of patients with cardiovascular comorbidities — including hypertension, chronic kidney disease, and diabetes — was more prevalent in adult patients with DCM. As expected, adult DCM patients
were more likely to have received antiremodeling therapies. Echocardiographic data confirmed depressed ejec-
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Figure 1. Absence of cardiomyocyte hypertrophy in pediatric DCM. (A)
Wheat germ agglutinin (WGA) staining (red) demonstrating that pediatric
donor controls and pediatric DCM specimens display similar cardiomyocyte
cross-sectional area. In contrast, adult DCM patients display increased
cardiomyocyte cross-sectional area compared with donor controls. Blue, DAPI
(nuclei). Magnification 400×. (B) Quantification of cardiomyocyte cross-sectional area. (C) Cardiomyocyte cross-sectional area stratified by age, revealing
that cardiomyocyte cross-sectional area does not differ from donor controls
across pediatric groups. *P < 0.05 (Mann Whitney U test). (D) Scatter plots
showing that cardiomyocyte cross-sectional area does not differ as a function of age in pediatric DCM patients. In contrast, adult DCM patients have
increased cardiomyocyte cross-sectional area at all ages examined.

tion fraction and fractional shortening, as well as increased LV systolic
and diastolic chamber dimensions in both the adult and pediatric DCM
groups. LV ejection fraction was slightly lower in the adult DCM cohort.
Examination of available clinical data obtained from pediatric and adult
donor controls demonstrated similar sex distribution and ejection fraction. There were a higher proportion of adult donor controls who had
stroke listed as the cause of brain death (Table 2).
Cardiomyocyte hypertrophy. To examine the extent of cardiomyocyte hypertrophy, we stained pediatric and adult donor control and
DCM specimens with rhodamine conjugated wheat germ agglutinin
(WGA) and measured cardiomyocyte cross-sectional area (Figure
1A). Measurements were made perpendicular to the long axis of
each cardiomyocyte. Compared with donor control, pediatric DCM
specimens did not demonstrate evidence of increased cardiomyocyte cross-sectional area (271.8 ± 210 vs. 333.5 ± 184 μm2, P = 0.24).
Consistent with the presence of cardiomyocyte hypertrophy in adult
DCM, WGA staining revealed a marked increase in cardiomyocyte
cross-sectional area in adult DCM samples compared with donor
controls (416.5 ± 159 vs. 1,058 ± 420 μm2, P < 0.001) (Figure 1B).
Stratification of donor controls and DCM specimens by age group
further demonstrated that increased cardiomyocyte cross-sectional
area was only evident in adult age groups (Figure 1C). Stratification
of pediatric samples by age group (0–1, 1–10, 11–18 yrs) demonstrated no differences in cardiomyocyte cross-sectional area between
donor control and pediatric DCM samples. In contrast, adult DCM
samples displayed increased cardiomyocyte cross-sectional area in
19–50 and 51–65 yrs age groups. Linear regression analysis further
confirmed that only adult DCM samples displayed increased cardiomyocyte cross-sectional area throughout the spectrum of ages examined (Figure 1D).
To provide additional evidence that cardiomyocyte hypertrophy preferentially occurs in adult and
not pediatric DCM, we examined cardiomyocyte ultrastructure using transmission electron microscopy
(Figure 2A). Previous studies have established that pathologic cardiomyocyte hypertrophy is associated
with increased sarcomere thickness (11, 12). Compared with donor controls, pediatric DCM specimens
did not demonstrate any changes in sarcomere thickness (0.54 ± 0.04 vs. 0.62 ± 0.14 μm, P = 0.12). In
contrast, adult DCM specimens displayed increased sarcomere thickness (0.76 ± 0.12 vs. 1.25 ± 0.27 μm,
P < 0.01) compared with donor controls (Figure 2B).
Myocardial fibrosis. To determine whether pediatric and adult DCM specimens display evidence of
myocardial fibrosis compared with age-matched controls, we performed Picrosirius red staining, a specific
marker of collagen deposition (13). As anticipated, pediatric and adult donor control specimens displayed
Picrosirius red staining surrounding larger arteries and small blood vessels (perivascular space) and minimal staining around individual cardiomyocytes (interstitial space). Pediatric DCM specimens displayed
similar degrees of perivascular fibrosis and minimal interstitial fibrosis. In contrast, adult DCM specimens
insight.jci.org   https://doi.org/10.1172/jci.insight.94382
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demonstrated patchy areas of dense interstitial fibrosis and accentuated
perivascular fibrosis compared with donor controls (Figure 3A).
Pediatric donor
Adult donor
P value
Given the presence of two distinct patterns of myocardial fibrosis
n=
11
14
(interstitial and perivascular), we chose to employ two methods to
Age in yrs
11.3
50.0
<0.01
quantify myocardial fibrosis: i) total Picrosirius red staining, and ii)
Male
7/11 (63.6)
9/14 (64.3)
0.97
a semiquantitative scoring system to individually quantify the extent
EF (%)
54.0
61.7
0.71
of perivascular and interstitial fibrosis (Supplemental Figure 2). To
Cause of death
minimize potential bias, specimens were scored by two independent
Head trauma
4/11 (36.4)
4/14 (28.6)
0.68
investigators blinded to sample identity. Quantification of the perStroke
0/11 (0)
6/14 (42.9)
0.01
centage of Picrosirius red staining per 20× field revealed no evidence
Unknown
7/11 (63.6)
4/14 (28.6)
0.09
of myocardial fibrosis in pediatric DCM specimens compared with
Percentages displayed in parenthesis. EF, ejection fraction.
pediatric donor controls (1.7 ± 0.7 vs. 2.0 ± 0.3, P = 0.46). In contrast, adult DCM specimens displayed evidence of marked myocardial fibrosis compared with adult donor controls (1.8 ± 0.2 vs. 12.3 ±
1.1, P < 0.01) (Figure 3B). Quantification of fibrosis scores revealed no evidence of interstitial (0.10
± 0.3 vs. 0.41 ± 0.8, P = 0.08) or perivascular fibrosis (1.1 ± 0.7 vs. 0.52 ± 0.7, P = 0.05) in pediatric
DCM specimens compared with pediatric donor controls. In contrast, adult DCM specimens displayed
evidence of increased interstitial (0.2 ± 0.6 vs. 1.8 ± 0.8, P < 0.01) and perivascular (1.1 ± 0.8 vs. 1.6 ±
0.7, P = 0.03) fibrosis compared with adult donor controls (Figure 3C). Stratification of pediatric and
adult DCM samples by patient age using linear regression and subgroup analyses demonstrated minimal total, interstitial, or perivascular fibrosis across the spectrum of pediatric age groups (0–1, 1–10,
and 10–18 yrs). In contrast, prominent total, interstitial, and perivascular fibrosis was found in each
adult subgroup (19–50 and 51–75 yrs) consistent with prior reports (14) (Figure 3, D–F).
Coronary microvasculature. While conflicting data exist regarding whether coronary microvascular density is
reduced in adult patients with chronic DCM (15–17), it is well appreciated that reductions in myocardial perfusion and flow reserve are strong predictors of poor clinical outcomes (18–22). To date, few studies have examined
whether coronary microvascular density is altered in pediatric DCM. To clarify whether coronary microvascular
density is affected in pediatric DCM, we performed CD34 immunostaining on pediatric and adult donor control
and DCM specimens. Microvascular density was quantified by measuring the percentage of the myocardium that
displayed CD34 staining, a method we have previously demonstrated to tightly correlate with the number of capillaries present per high-power field (23).
Compared with pediatric donor controls,
coronary microvascular density was increased
in pediatric DCM (6.1% ± 0.9% vs. 10.9% ±
5.5%, P < 0.001). In contrast, adult donor
controls and adult DCM specimens displayed
similar microvascular density (6.7% ± 1.7% vs.
6.5% ± 2.0%, P = 0.72) (Figure 4, A and B).
When CD34 staining was further stratified by
age groups using either linear regression or subgroup analyses, we found that coronary microvascular density was increased across the spectrum of pediatric ages. In contrast, coronary
microvascular density was indistinguishable
from adult donor controls across each adult
DCM age group (Figure 4, C and D).

Table 2. Donor control demographic data

Figure 2. Sarcomere structure in pediatric and adult DCM. (A) Electron microscopy
examining sarcomere structure in donor control, pediatric, and adult DCM specimens.
Compared with donor controls, pediatric DCM patients display no change in sarcomere
thickness. In contrast, adult DCM patients demonstrate increased sarcomere thickness
compared with donor controls. (B) Quantification of sarcomere thickness. Each data
point represents an average of >20 sarcomeres measured from individual patient samples. P values found with Mann Whitney U test.
insight.jci.org   https://doi.org/10.1172/jci.insight.94382
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Figure 3. Absence of myocardial fibrosis in pediatric DCM. (A) Picrosirius red staining (red) demonstrating that, compared with donor controls, pediatric
DCM specimens display minimal interstitial or perivascular fibrosis. In contrast, adult DCM patients display increased interstitial and perivascular fibrosis
compared with donor controls. Magnification 200×. (B) Quantification of percent fibrosis as assessed by total Picrosirius red staining per 20× field in pediatric and adult control and DCM specimens. (C) Quantification of interstitial and perivascular fibrosis scores. (D) Scatter plots showing that the percent
of Picrosirius staining in pediatric DCM specimens does not differ from donor pediatric controls across the spectrum of child age. In contrast, adult DCM
patients have increased Picrosirius red staining at all ages examined. (E and F) Total Picrosirius red staining (E) and fibrosis scores (F) stratified by age,
revealing that interstitial and perivascular fibrosis scores are only increased in adult groups. *P < 0.05 (χ2 test), ***P < 0.05 (compared to pediatric groups).

Adverse remodeling, disease duration, and comorbidities. As the duration of disease significantly differs
between pediatric and adult DCM, with adult patients having longer periods of disease (24–26) (Table
1), we viewed heart failure duration as a confounding variable that may potentially explain why children
with DCM display less adverse remodeling compared with adult DCM patients. To account for disease
duration (defined as the period of time between clinical diagnosis of heart failure and myocardial specimen
collection), we divided our adult DCM cohort into three groups: disease duration less than 1 year, disease
duration 1–5 years, and disease duration greater than 5 years.
insight.jci.org   https://doi.org/10.1172/jci.insight.94382

5

RESEARCH ARTICLE

Figure 4. Microvascular alterations in pediatric and adult DCM.
(A) CD34 immunostaining demonstrating that, compared with
donor controls, pediatric DCM specimens display increased
microvascular density. In contrast, adult DCM patients have
indistinguishable microvascular density compared with donor
controls. Magnification 200×. (B) Quantification of microvascular density expressed as the percent of staining per 20× field.
(C) Scatter plots showing that pediatric DCM patients display
increased capillary density compared with donor controls across
the spectrum of child ages. In contrast, capillary density did not
differ between adult DCM specimens and donor controls at all
ages examined. (D) CD34 staining stratified by age, revealing
that microvascular density is increased in all pediatric groups. *P
< 0.05 (Mann Whitney U test).

Compared with donor controls, adult DCM patients
who were diagnosed with heart failure for less than 1 year
displayed similar increases in cardiomyocyte cross-sectional
area compared with those diagnosed with heart failure for
1–5 years and greater than 5 years (Figure 5, A and B). While
there was a trend for increased cardiomyocyte cross-sectional
area with longer disease durations, these relationships were
not statistically significant, suggesting that cardiomyocyte
hypertrophy occurs largely independent of disease duration.
Similarly, the extent of myocardial fibrosis (Figure 5, C–F)
and coronary microvascular density (Figure 5, G and H)
were not influenced by disease duration. Stratification of
pediatric DCM patients by disease duration revealed no relationship between disease duration, cardiomyocyte hypertrophy, and myocardial fibrosis (Figure 5, I and J).
As the frequency of hypertension, chronic kidney
disease, and diabetes was significantly increased in adult
compared with pediatric DCM patients, we performed
independent analyses to control for these confounding
variables. Compared with donor controls, patients with DCM displayed increased cardiomyocyte hypertrophy and myocardial fibrosis independent of the presence of hypertension, chronic kidney disease, and
diabetes (Supplemental Figure 3). Collectively, these data signify that disease duration and cardiovascular
comorbidities, including hypertension, chronic kidney disease, and diabetes, are unlikely to account for the
observed differences in pathological adverse remodeling between pediatric and adult DCM specimens.
RNA sequencing. To determine whether pediatric and adult DCM represent similar or distinct pathological
entities at the transcriptomic level, we performed RNA sequencing. Of the LV myocardial tissues included in
this study, 18 pediatric and 33 adult DCM specimens were of suitable quality for RNA sequencing and subsequent analysis (Table 3). Of note, we chose not to include donor control samples in our RNA sequencing
experimental design, as these specimens are obtained from donor hearts that are not suitable for transplantation due to prolonged ischemic times, profound end organ failure, advanced age, hepatitis C/HIV, and preexisting cardiac disease. With respect to this study, we excluded donors with hepatitis C, HIV, and preexisting
cardiac disease. Importantly, brain death itself has been demonstrated to increase inflammation within the
heart (27, 28). Thus, donor specimens obtained from brain-dead individuals are unlikely to represent normal
cardiac tissue. While these tissues do not appear to demonstrate chronic pathological changes, they likely have
significant derangements in gene expression and would potentially compromise our RNA sequencing analysis. For this reason, we have excluded such controls and recognize age as a potential confounding variable.
In support of the hypothesis that pediatric and adult DCM represent distinct pathological entities,
principal component analysis demonstrated clear distinctions between pediatric and adult groups (Figure
6A). Similarly, differential gene expression analysis identified numerous transcripts that were selectively
regulated in pediatric and adult DCM specimens across the entire spectrum of transcript abundance
(Figure 6B). Among the differentially regulated transcripts, 387 mRNAs were upregulated in pediatinsight.jci.org   https://doi.org/10.1172/jci.insight.94382
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ric DCM and 223 mRNA were upregulated in adult
DCM by greater than or equal to 2-fold. Likewise, 915
Pediatric DCM
adult DCM
P value
mRNAs were upregulated in pediatric DCM and 1,018
Total input reads
38,183,302.6 38,260,819.6
0.96
mRNAs were upregulated in adult DCM by greater
Uniquely mapped reads
32,244,707.4 32,504,594.3
0.84
than or equal to 1.5-fold (Figure 6C).
Uniquely mapped reads (%)
84.5
84.9
0.63
Consistent with the observation that adverse remodMismatch rate per base (%)
0.16
0.12
<0.01
eling selectively occurs in adult DCM, genes previously
Reads mapped to multiple loci
4,832,155.6
4,961,119.8
0.76
associated with pathological cardiomyocyte hypertrophy
Reads mapped to multiple loci (%)
12.5
12.9
0.64
in humans and animal models (Nppa, Myh7, Mybpc3,
Unmapped reads (%)
2.1
1.4
0.07
Actc1, Tpm1, Des, Lmna, Myl3, Mylk3, Pln, Gdf15,
and Mef2) (29–32) were upregulated in adult compared
with pediatric DCM. Myh6, a gene that is known to
decrease with pathological cardiomyocyte hypertrophy, was downregulated in adult compared with pediatric DCM (Figure 6D). In addition to differential regulation of genes associated with adverse remodeling,
Gene Ontology (GO) pathway analysis revealed selective regulation of several other interesting pathways
(Table 4). Pathways upregulated in adult DCM included those associated with oxidative reduction, fatty acid
metabolism, response to endogenous stimuli and organic substances, and inflammatory/wounding responses. While differences in substrate utilization and β-adrenergic signaling have been previously described in
pediatric and adult heart failure (10, 33, 34), distinctions in inflammation have yet to be explored. Among the
genes associated with inflammation, numerous proinflammatory chemokines, cytokines, danger signals, key
signal transduction components, and transcription factors were selectively upregulated in adult DCM (Figure
6E and Supplemental Table 1). Pathways upregulated in pediatric DCM included those previously associated
with cell adhesion, ion and transmembrane transport, and visual perception. Among the genes associated
with visual perception, many — to our knowledge — represented novel G-protein coupled receptors with
similarity to retinal photoreceptors (Supplemental Table 2).
As noted above, we did not include pediatric and adult donor control samples in our analysis. As such, we
recognized a priori that age may represent a confounding factor. To evaluate the impact of age on the observed
differences between pediatric and adult DCM transcript expression, we performed a hierarchical clustering
analysis based on mRNAs differentially expressed between pediatric and adult DCM groups. Importantly,
this analysis illustrated that pediatric and adult DCM specimens cluster as two distinct entities rather than as
a continuum of age. Within each of the pediatric and adult subgroups, individual specimens are randomly
distributed by age (Figure 6F). Collectively, these data support the concept that adverse remodeling selectively
occurs in adult DCM and that pediatric and adult DCM represent distinct pathological entities.

Table 3. RNA sequencing analysis

Discussion
This study tested the hypothesis that pediatric and adult DCM represent distinct pathological entities, in that
children do not undergo adverse remodeling. Collectively, our data support this hypothesis and provide evidence that distinct pathological mechanisms drive the progression of pediatric and adult DCM. Specifically,
we demonstrated that adverse remodeling does not uniformly occur in children with DCM, as myocardial
specimens obtained from patients with pediatric DCM display no significant cardiomyocyte hypertrophy,
increased sarcomere thickness, or myocardial fibrosis compared with age-matched donor controls. In contrast, myocardial specimens obtained from adults with DCM displayed robust increases in cardiomyocyte
size, sarcomere thickness, and myocardial fibrosis compared with age-matched donor controls. Importantly,
these findings appear to be irrespective of patient age across pediatric and adult subgroups, and they appear
to be independent of disease duration at least within the adult cohort. Consistent with the pathological data,
RNA sequencing revealed divergent gene expression profiles between pediatric and adult DCM tissue specimens, with adult specimens displaying marked induction of transcripts associated with adverse remodeling.
To date, this is the first study to have rigorously evaluated whether adverse remodeling occurs in children and to compare myocardial gene expression in a large cohort of pediatric and adult DCM patients.
Our results have important clinical implications and may explain several key observations that differentiate
pediatric from adult DCM. The establishment of large clinical registries such as the Pediatric Cardiomyopathy Registry (PCMR) and execution of randomized clinical trials has made it possible to define the clinical
course and outcomes for pediatric DCM (1, 7, 35, 36). Children with DCM display remarkable variability
in overall outcomes, ranging from complete recovery of cardiac function (referred to as cardiac recovery)
insight.jci.org   https://doi.org/10.1172/jci.insight.94382
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Figure 5. Disease duration does not influence pathological evidence of adverse remodeling in adult and pediatric DCM. (A) Quantification of cardiomyocyte cross-sectional area stratified by disease
duration reveals that patients diagnosed with heart failure < 1 year,
1–5 years, or < 5 years prior to tissue procurement displayed marked
cardiomyocyte hypertrophy compared with donor controls. No significant differences were evident between disease duration groups.
(B) Linear regression analysis describing the relationship between
cardiomyocyte cross-sectional area and disease duration. (C) Quantification of total Picrosirius red staining stratified by disease duration reveals that patients diagnosed with heart failure < 1 year, 1–5
years, or < 5 years prior to tissue procurement displayed increased
fibrosis compared with donor controls. (D) Linear regression analysis
describing the relationship between total Picrosirius red staining
and disease duration. (E and F) Quantification of interstitial and
perivascular fibrosis stratified by disease duration demonstrates
that myocardial fibrosis occurs independent of disease duration.
No significant differences were evident between disease duration
groups. (G and H) Quantification of CD34 staining stratified by disease duration demonstrates no relationship between microvascular
density and disease duration. (I and J) Quantification of myocardial
fibrosis (I) and cardiomyocyte cross-sectional area (J) stratified by
disease duration reveals that children diagnosed with heart failure <
1 year or < 1 year prior to tissue procurement displayed no indistinguishable levels of myocardial fibrosis and cardiomyocyte hypertrophy compared with donor controls. No significant differences were
evident between disease duration groups. *P < 0.05 compared with
donor control. Mann Whitney U test (A, C, G) or χ2 test (E and F).

to disease progression and need for cardiac transplantation
or mechanical circulatory support (37). Interestingly, a competing-outcomes analysis demonstrated that, within 2 years
of diagnosis, children with DCM will experience sustained
disease stabilization, cardiac recovery, or disease progression (cardiac mortality or transplantation) (26). The mechanisms that orchestrate why individual children experience
each of these outcomes remain poorly defined.
One of the most apparent distinctions between pediatric and adult DCM is the repeated observation that
antiremodeling medications routinely used to treat adult
heart failure patients do not significantly improve outcomes in children. The Pediatric Carvedilol Trial failed
to demonstrate significant improvements in either clinical
outcomes or echocardiographic parameters in children
with DCM (7). In addition, registry data revealed that
children with DCM treated with angiotensin converting
enzyme (ACE) inhibitors or β-blockers had indistinguishable survival compared with those only receiving digoxin- and diuretic-based regimens (1, 9). Our
data provides a mechanistic rationale for why children do not respond to adult heart failure therapeutics and strongly suggest that prognostic and therapeutics strategies routinely used in adults may
have limited clinical utility in the pediatric population. These results are consistent with prior studies
showing that hallmarks of adverse remodeling, including β-adrenergic receptor downregulation, fetal
gene expression, and fibrosis, occur to a lesser extent in pediatric DCM (10, 38). In addition, the lack
of myocardial fibrosis in pediatric patients with DCM may provide an explanation as to why sudden
death is more prevalent in adult compared with pediatric DCM patients (39).
Disease duration represented a potential important variable that differed between the pediatric and
adult DCM cases. Controlling for disease duration in our adult cohort demonstrated that increased disease
duration in adult DCM did not constitute the primary reason why cardiomyocyte hypertrophy and myocarinsight.jci.org   https://doi.org/10.1172/jci.insight.94382
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Table 4. GO pathway analysis
Increased expression in adult DCM, n = 1,018

genes

P value

Fold enrichment

GO:0055114: oxidation reduction
GO:0009719: response to endogenous stimulus
GO:0010033: response to organic substance
GO:0009611: response to wounding
GO:0006954: inflammatory response
GO:0006631: fatty acid metabolic process
Increased expression in pediatric DCM, n = 915
GO:0006811: ion transport
GO:0007155: cell adhesion
GO:0055085: transmembrane transport
GO:0007601: visual perception

67
47
70
51
35
25
genes
59
54
43
19

2.40 × 10–7
1.35 × 10–6
2.10 × 10–6
8.05 × 10–5
1.66 × 10–4
1.71 × 10–4
P value
1.33 × 10–8
5.56 × 10–8
2.77 × 10–6
5.06 × 10–4

1.94
2.15
1.80
1.78
2.00
2.33
Fold Enrichment
2.22
2.23
2.18
2.54

dial fibrosis occurred at dramatically higher frequency in adult DCM patients. However, there was a trend
(P = 0.09) between increased disease duration and greater extents of cardiomyocyte hypertrophy in adult
DCM. Examination of disease duration in the pediatric DCM groups revealed no significant relationship
between disease duration, cardiomyocyte hypertrophy, or adverse remodeling. Of note, statistically nonsignificant trends suggested that cardiomyocyte hypertrophy may be exaggerated by hypertension and chronic
kidney disease. These data suggest that, within the adult DCM cohort, disease duration, hypertension, and
chronic kidney disease may contribute to the extent of adverse remodeling. Importantly, these relationships
were limited by sample size and should be viewed as speculative.
The apparent absence of adverse remodeling in pediatric DCM raises the question of what distinct disease mechanisms drive heart failure progression in children. In adult patients with ischemic and
dilated cardiomyopathies, it is clear that heart failure initiation and progression are driven by separate
pathophysiological processes (i.e., myocardial infarction or genetic mutations and adverse remodeling,
respectively) (40, 41). Whether the failing pediatric heart follows a similar paradigm and undergoes a
distinct remodeling program or whether disease progression is simply governed by the underlying cause
of the cardiomyopathy is unclear. Future studies clarifying these mechanisms will be essential to guide
effective therapeutic strategies for children with DCM.
The capacity to recover cardiac function (i.e., cardiac recovery), represents an important difference
between pediatric and adult DCM. Approximately 20% of children diagnosed with pediatric DCM will
spontaneously and completely recover LV systolic function over a two-year follow-up period (37). In contrast, cardiac recovery is a relatively infrequent outcome in the adult patients with chronic heart failure (42,
43). The observation that cardiac recovery occurs spontaneously in the pediatric population was further
demonstrated in the Pediatric Carvedilol Trial, where children in both the placebo and carvedilol groups
displayed improved LV systolic function through the course of the study (7). These observations suggest
that cardiac recovery represents an achievable outcome and a potential target for pediatric heart failure
therapeutics. Consistent with this concept, previous reports have indicated that patients who experience
cardiac recovery have improved quality of life and long-term survival (44).
The underlying mechanisms that dictate cardiac recovery and explain why children have a greater
capacity for cardiac recovery compared with adults are poorly defined. The absence of adverse remodeling
in pediatric DCM patients may represent one such explanation. Indeed, we and others have previously
demonstrated that, in a mouse model of pediatric cardiac recovery, adverse remodeling only occurs in
animals that lack the capacity to replace lost cardiomyocytes and expand the coronary vasculature (45–47).
Consistent with these animal models, it has previously been demonstrated that children have a greater
capacity for cardiomyocyte proliferation compared with adults (48), and in this study, we showed that coronary microvascular expansion occurs in pediatric but not adult DCM.
The molecular basis explaining why pediatric and adult DCM have differential capacity for cardiac recovery
and distinct pathologies (i.e., adverse remodeling) are poorly defined. Using RNA sequencing, we compared the
transcriptomes of 18 pediatric and 33 adult DCM patients, the largest study reported to date, to our knowledge.
Strikingly, more than 1,900 mRNA transcripts were differentially regulated between pediatric and adult DCM
using an FDR < 0.05 and fold change > 1.5. In addition to differential expression of transcripts associated with
insight.jci.org   https://doi.org/10.1172/jci.insight.94382
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Figure 6. RNA sequencing analysis. (A) Principal component analysis demonstrating segregation of pediatric and adult DCM samples. (B) Bland-Altman
(MA) plot depicting the relationship between differential gene expression and transcript abundance in pediatric and adult DCM samples. (C) Differential gene
expression analysis highlighting the number of mRNA transcripts that are differentially expressed by 1.5- and 2-fold in pediatric and adult DCM samples. (D
and E) mRNA transcripts associated with sarcomere remodeling (D) and inflammation (E) are differentially regulated in pediatric and adult DCM. (F) Hierarchical clustering analysis illustrating that pediatric and adult DCM samples cluster as two distinct entities rather than as a continuum of age. Ped, pediatric.

adverse remodeling, pathway analysis revealed that adult specimens displayed marked induction of transcripts
associated with innate immune system activation, fatty acid and oxidative metabolism, and metabolite signaling.
These data confirm the importance of metabolism and substrate utilization in adult heart failure and signify the
potential relevance of innate immune activation in the pathogenesis of adult DCM.
A wealth of literature has established that the failing adult heart displays important restrictions in
substrate availability and utilization (49). Under resting conditions, the healthy adult heart metabolizes a
diverse array of substrates including glucose, fatty acids, amino acids, and ketones. When the healthy heart
insight.jci.org   https://doi.org/10.1172/jci.insight.94382
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is faced with periods of stress, glucose and, to a lesser extent, free fatty acid utilization increases (50). In
contrast, metabolic derangements in the chronically failing adult heart result in restricted substrate utilization. While fatty acid oxidation is maintained in early stages of adult heart failure (51, 52), reductions in
fatty acid uptake and utilization occur during the course of disease progression (53). Consistent with the
loss of metabolic flexibility, the chronically failing adult heart is unable to augment glucose uptake during
periods of stress (54, 55). These metabolic perturbations are thought to be due to a complex interplay of
mechanisms, including insulin resistance, mitochondrial dysfunction, and neurohormonal activation (56,
57). Interestingly, increased sympathetic outflow and plasma norepinephrine levels in adult heart failure
are associated with the development of insulin resistance, circulating fatty acids, and impaired glucose
utilization linking metabolic derangements to adverse remodeling (58). With the exception of differing
sensitivities to ischemia (33), little is known regarding metabolism in the pediatric heart.
Previous studies have established that innate immune activation is associated with the onset and progression of heart failure in adult patients. Circulating levels of TNFα, IL1β, and IL6 are elevated in adults with
chronic heart failure and are predictive of poor prognosis (59–63). While the precise mechanisms that orchestrate proinflammatory responses in adult heart failure are not completely understood, it is clear that inhibition
of inflammatory cytokine signaling may be beneficial (64). Blockade of IL1β signaling improves LV systolic
function and suppresses components of adverse remodeling, including cardiomyocyte hypertrophy and myocardial fibrosis (65–70). As such, IL1β antagonists are under clinical investigation as novel therapeutics for
adults with acute myocardial infarction (MI) and heart failure (71, 72). While reduced inflammatory gene
expression in pediatric DCM may suggest that antiinflammatory approaches may be less efficacious in children, future studies will be required to directly test the feasibility of IL1β blockade in pediatric heart failure.
In comparison with adult DCM, pediatric specimens displayed induction of transcripts associated with cell adhesion, ion and transmembrane transport, and a variety of novel G-protein coupled
receptors similar to those utilized for visual perception. Based on the current literature, the functional
relevance of these genes and pathways with respect to the pathophysiology of pediatric heart failure is
not immediately apparent. Whether these gene expression changes represent adaptive or maladaptive
responses to pediatric DCM remains unclear but will undoubtedly be the subject of future investigation in suitable preclinical models.
Limitations. While this study represents, to our knowledge, the largest cohort of pediatric and adult
DCM specimens studied to date, sample size remains an important limitation. Although the overall
pediatric and adult populations were of sufficient size for comparative analyses, secondary subgroup
analyses (i.e., age subgroups) were limited by sample size and, as such, should be interpreted with caution. In addition, this analysis is limited by the availability of clinical data, including genetic analyses
identifying causative variants. Thus, covariates in addition to patient age may contribute to differences
in adverse remodeling and gene expression. For example, in the absence of genetic data, it is not possible to directly compare pediatric and adult DCM samples harboring similar mutations. However, given
the robust differences observed across pediatric and adult cohorts, it is likely patient age (pediatric vs.
adult) represents a major component. The omission of control specimens represents an inherent limitation of our RNA sequencing analysis. As control specimens are typically obtained from brain-dead
donors that are not suitable for transplantation due to preexisting cardiac disease, hepatitis C/HIV,
prolonged ischemic times, and end organ failure, they do not represent normal cardiac tissue. While
these tissues do not appear to demonstrate chronic pathological changes, they likely have significant
derangements in gene expression, and that would likely confound our RNA sequencing analysis. For
this reason, we excluded donor controls from the RNA sequencing analysis and recognize age as a
confounding variable. Lastly, it is currently unknown whether our findings extend to other etiologies
of pediatric heart failure, including hypertrophic cardiomyopathy, chemotherapy-induced cardiomyopathy, or even single-ventricle myocardial dysfunction. Future studies should investigate whether and
to what extent adverse remodeling occurs in these disease settings.
Conclusions. Collectively, our findings support the concept that pediatric and adult DCM represent
distinct pathological entities and provide a mechanistic basis to explain why children with DCM fail to
respond to antiremodeling medications commonly used in adult heart failure patients. Together, these
observations support a shift in clinical management of pediatric DCM and suggest that it may be appropriate to revise therapeutic approaches for children stricken with this devastating disease.
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Methods
Pathologic specimens. Cardiac tissue specimens were obtained from pediatric and adult patients with idiopathic and familial DCM undergoing LVAD implantation or cardiac transplantation. Patients with secondary causes of DCM, including cardiac amyloidosis, cardiac sarcoidosis, viral myocarditis, giant cell myocarditis, peripartum cardiomyopathy, and complex congenital heart disease, were excluded from this study.
In addition, children who were classified as having neuromuscular disease–related cardiomyopathy, metabolic/mitochondrial disorder, or myocarditis on the basis of clinical presentation or biopsy were excluded.
Adults with ischemic cardiomyopathy, chemotherapy-associated cardiomyopathy, and alcohol-induced
cardiomyopathy were excluded. Tissues consisted of transmural specimens obtained from the apical or
lateral wall of the LV. Cardiac tissue specimens (donor control and DCM) were either immediately flash
frozen or fixed in 10% formalin upon collection to preserve tissue integrity. Pediatric DCM specimens were
acquired from the PCMR tissue repository and the Washington University Translational Cardiovascular
Biobank and Repository (TCBR). Pediatric donor control specimens were obtained from the University of
Colorado (Boulder, Colorado, USA). Control specimens acquired from brain-dead patients with normal
LV systolic function and LV dimensions by echocardiography that were deemed not suitable for cardiac
transplantation. Adult donor control and DCM specimens were obtained from the TCBR. The PCMR
repository and the TCBR tissue bank diagnostic criteria for DCM was based on echocardiographic measurements related to LV enlargement and depressed systolic function, pathologic findings at autopsy, explanation or biopsy, and clinical evidence by the diagnosing cardiologist.
Cardiomyocyte hypertrophy. To evaluate for cardiomyocyte hypertrophy, rhodamine-conjugated WGA
staining was used to demarcate plasma membrane boundaries on tissue sections of cardiomyocytes in
cross section. Myocardial specimens were fixed in 10% formalin for 72 hours. Tissues were embedded in
paraffin and 4-μm sections obtained using a Leica microtome. Paraffin sections were dewaxed with xylene,
rehydrated, blocked with 1% BSA, and stained rhodamine-conjugated WGA (Vector Laboratories, 1:200).
Sections were then washed and mounted in Vectashield with DAPI (Vector Laboratories). At least 5 images
per specimen were obtained on a Zeiss Confocal Microscope at 20× magnification. Serial sections were
used to identify cardiomyocytes that were oriented perpendicular to the long axis. Cross-sectional area was
measured using AxioVision software. For each individual, at least two separate myocardial specimens were
examined and >20 cardiomyocytes per specimen were measured by two observers blinded to the experimental group. The criteria for cardiomyocytes to be included in the analysis consisted of cross-sectional
morphology and the presence of DAPI-stained nuclear material.
Myocardial fibrosis. To evaluate for myocardial fibrosis, we stained for collagen using Picrosirius red
(Thermo Fisher Scientific). Paraffin-embedded sections were dewaxed in xylene, rehydrated, stained with
Picrosirius red for 20 minutes, washed in acid water, dehydrated, and mounted in a xylene-based media
(Cytoseal, Thermo Fisher Scientific). For each individual, multiple fields from at least two separate myocardial specimens were included in the final analysis. A scoring system was utilized to measure the degrees
of perivascular fibrosis and interstitial fibrosis to allow discrimination of distinct patterns of fibrosis. Scoring was performed by two observers blinded to the experimental group, with results averaged for each
patient. The scoring protocol is outlined in Supplemental Figure 1.
Capillary staining. To measure coronary microvascular density, we performed IHC with an anti-CD34
(QBEnd/10, Abcam) antibody (catalog ab8536). The CD34 antibody was chosen due to previous reports
demonstrating excellent signal intensity across a variety of specimens (23). Paraffin-embedded sections were
dewaxed in xylene, rehydrated, blocked in 1% BSA, and stained with anti-CD34 (1:400) antibody overnight.
The primary antibody was detected using a biotin conjugated anti–mouse secondary antibody (Vector Laboratories) in conjunction with streptavidin HRP (ABC Elite, Vector Laboratories) and DAB reagent (Vector
Laboratories). Slides were then dehydrated and mounted in a xylene-based media (Cytoseal). Photographs
were acquired at 20× on a Zeiss Axioskope system. For each individual, at least two separate myocardial
specimens were included. Microvascular density was measured from at least 2–3 slides per specimen using
Image J software as previously described (23). Using this methodology, we previously demonstrated that automated measurement of the percent area stained was highly correlated with manual counting of the number
of capillaries per field. The averaged values from > 5 images per individual were included in the final analysis.
Electron microscopy. Cardiac specimens (2 mm2) were fixed in a mixture of 2.5% glutaraldehyde and
2% paraformaldehyde in 0.15 M cacodylate buffer at pH 7.4 containing 2 mM calcium chloride at 4˚C
overnight. Sample were rinsed in 0.15 M cacodylate buffer 3× for 10 minutes each and subjected to a
insight.jci.org   https://doi.org/10.1172/jci.insight.94382
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secondary fixation step for 1 hour in 1% osmium tetroxide containing 1.5% potassium ferrocyanide
in cacodylate buffer on ice. Following fixation, samples were then washed in ultrapure water 3× for
10 minutes each and en bloc stained for 1 hour with 2% aqueous uranyl acetate. All reagents listed in
previous sentences are from Sigma-Aldrich. After staining was complete, samples were briefly washed
in ultrapure water, dehydrated in a graded acetone series (50%, 70%, 90%, 100% ×2) for 10 minutes
in each step, infiltrated with microwave assistance (Pelco BioWave Pro) into LX112 resin, embedded
in silicone molds, and cured in an oven at 60˚C for 48 hours. Once the resin was cured, each block
was trimmed and faced using a diamond trim tool (Leica EM TRIM2). Longitudinal sections (70 nm)
were obtained and imaged on a FE-SEM (Zeiss Crossbeam 540) using the aSTEM detector. The SEM
was operated at 28 KeV with a probe current of 0.9 nA, and the STEM detector was operated with
the annular rings inverted for additional sample contrast. Large sample areas were imaged at a resolution of 4,096 × 3,072 pixels, with a pixel size of 5.582 nm. Sarcomere thickness was measured in
two samples per specimen by individuals blinded to sample identity. Greater than 20 sarcomeres were
measured from each individual patient sample, and the average sarcomere thickness was calculated.
RNA sequencing. Total RNA was harvested from transmural pediatric and adult DCM samples
(200–400 mg) by disrupting samples in Trizol (Thermo Fisher Scientific) using the Qiagen TissueLyser
homogenizer with stainless steel beads. Following phenol chloroform extraction, RNA was purified
using the Ambion Purelink miniprep kit. RNA integrity was quantified on an Agilent Bioanalyzer,
and samples with RNA Integrity Number > 8 were utilized for RNA sequencing. Ribosomal RNAs
were depleted with Ribo-Zero, cDNA libraries were generated, and samples were sequenced (1 × 50
bp reads) on an Illumina HiSeq 3000 instrument. Sequence alignment, normalization, and differential
expression analysis was carried out in the Genome Technology Access Center at Washington University using Limma-Voom software. PCA and Hierarchical cluster analysis was performed in Partek.
GO Pathway analysis was performed using DAVID. Transcripts with > 10 reads in 50% of samples
demonstrating a fold change > 1.5-fold at an FDR < 0.05 were included in the pathway analysis. Raw
data was deposited in the NCBI sequence reads archive (SRA, SRP108128).
Statistics. Primary comparisons were made between control and DCM groups for each age group. Fisher’s exact and Mann-Whitney U tests with appropriate Bonferroni correction were used to identify statistically significant differences between groups. Data are presented as either dot plots or bar graphs, with all
data points displayed (mean ± SD).
Study approval. This study was approved by the Washington University in St. Louis IRB (protocal number 201305086) . All subjects provided informed consent prior to sample collection, and the experiments
were performed in accordance with the approved study protocol.
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